Model combination

How Certara’s predictive modeling software could help immuno-oncology combo trials

Certara L.P.’s latest precompetitive consortium is designed to solve the complexities of combination immuno-oncology therapy through in silico modeling.

The new Immuno-oncology Simulator Consortium is using Certara’s Quantitative Systems Pharmacology (QSP) platform and preclinical and clinical data from six undisclosed biopharmas to build a large-scale mechanistic model of the underlying immuno-oncology biology

Read the full 519 word article

How to gain access

Continue reading with a
two-week free trial.